Sorry to hear Vogelworld. ONJ is not a common side effect but with so many people on antiresorptive therapy, it will be seen. Deaths in trials are likely to happen - i.e. there could very well be one or more deaths in PARs phase III trials given the large patient group, generally older population and long follow-up period. That's not to say it's due to the drug though. People die due to complications of statin therapy, and how many people are on statins.. extremely low-risk but it happens.
Ann: Quarterly Update and Appendix 4C - quarterly, page-16
-
- There are more pages in this discussion • 31 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.0¢ |
Change
0.035(12.7%) |
Mkt cap ! $108.4M | |||
| Open | High | Low | Value | Volume |
| 27.5¢ | 31.0¢ | 27.5¢ | $108.9K | 371.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 17420 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |